Daniel Spratt

Case Comprehensive Cancer Center NCTN Lead Academic Participating Site

National Cancer Institute · UG1

PI · $6.7M · Case Western Reserve University

Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate Cancer

National Cancer Institute · U01

Contact PI · $1.8M · Case Western Reserve University

Determining the Clinical Impact of Gene Expression Testing in Localized Prostate Cancer

National Cancer Institute · R01

PI · $3.1M · University of Michigan at Ann Arbor

Individualized Estimates of Treatment Benefit from Hormone Therapy for Men with Prostate Cancer

National Cancer Institute · R21

PI · $386.9K · University of Michigan at Ann Arbor

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

Principal investigator · Active not recruiting

University of Michigan Rogel Cancer Center

Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer

Principal investigator · Completed · Phase 1

University of Michigan Rogel Cancer Center

Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma

Principal investigator · Terminated

University of Michigan Rogel Cancer Center

Hypofractionated Stereotactic Body Radiation Therapy (SBRT)

Principal investigator · Completed · Phase 2

University of Michigan Rogel Cancer Center